Literature DB >> 20668648

NANOTECHNOLOGY IN THE TREATMENT AND DETECTION OF INTRAOCULAR CANCERS.

Ashwin Nair1, Paul Thevenot, Wenjing Hu, Liping Tang.   

Abstract

Tremendous progress in nanotechnology has lead to the development of nanometer-sized objects as medical implants or devices. Many of these nanodevices have recently been tested in many cancer diagnostic and therapeutic applications, such as leukemia, melanoma, breast tumor, prostate tumor, and brain cancer. Despite the increasing importance of nanotechnology in cancer, the potential of these nanodevices in diagnosing and treating intraocular cancers has not been systematically evaluated. This review summarizes the significant advancements and potential areas for development in the field of nanotechnology-based intraocular drug delivery and imaging.

Entities:  

Year:  2008        PMID: 20668648      PMCID: PMC2910442          DOI: 10.1166/jbn.2008.004

Source DB:  PubMed          Journal:  J Biomed Nanotechnol        ISSN: 1550-7033            Impact factor:   4.099


  78 in total

1.  Ocular disposition and tolerance of ganciclovir-loaded albumin nanoparticles after intravitreal injection in rats.

Authors:  Marta Merodio; Juan Manuel Irache; Fatemeh Valamanesh; Massoud Mirshahi
Journal:  Biomaterials       Date:  2002-04       Impact factor: 12.479

2.  Size-dependent disposition of nanoparticles and microparticles following subconjunctival administration.

Authors:  Aniruddha C Amrite; Uday B Kompella
Journal:  J Pharm Pharmacol       Date:  2005-12       Impact factor: 3.765

Review 3.  Eye cancer: unique insights into oncogenesis: the Cogan Lecture.

Authors:  J William Harbour
Journal:  Invest Ophthalmol Vis Sci       Date:  2006-05       Impact factor: 4.799

4.  Biomimetic hydrogels for enhanced loading and extended release of ocular therapeutics.

Authors:  Siddarth Venkatesh; Stephen P Sizemore; Mark E Byrne
Journal:  Biomaterials       Date:  2006-09-26       Impact factor: 12.479

Review 5.  Industrial perspective in ocular drug delivery.

Authors:  Yusuf Ali; Kari Lehmussaari
Journal:  Adv Drug Deliv Rev       Date:  2006-09-15       Impact factor: 15.470

6.  Effect of particle size of polymeric nanospheres on intravitreal kinetics.

Authors:  E Sakurai; H Ozeki; N Kunou; Y Ogura
Journal:  Ophthalmic Res       Date:  2001 Jan-Feb       Impact factor: 2.892

Review 7.  Review of ocular drug delivery.

Authors:  Yasmin Sultana; R Jain; M Aqil; Asgar Ali
Journal:  Curr Drug Deliv       Date:  2006-04       Impact factor: 2.565

Review 8.  Retinoblastoma: review of current management.

Authors:  Murali Chintagumpala; Patricia Chevez-Barrios; Evelyn A Paysse; Sharon E Plon; Richard Hurwitz
Journal:  Oncologist       Date:  2007-10

9.  Release of ciprofloxacin from poloxamer-graft-hyaluronic acid hydrogels in vitro.

Authors:  K Y Cho; T W Chung; B C Kim; M K Kim; J H Lee; W R Wee; C S Cho
Journal:  Int J Pharm       Date:  2003-07-09       Impact factor: 5.875

10.  Poly(N-isopropylacrylamide)-chitosan as thermosensitive in situ gel-forming system for ocular drug delivery.

Authors:  Yanxia Cao; Can Zhang; Wenbin Shen; Zhihong Cheng; Liangli Lucy Yu; Qineng Ping
Journal:  J Control Release       Date:  2007-05-17       Impact factor: 9.776

View more
  3 in total

1.  Development of a novel bioerodible dexamethasone implant for uveitis and postoperative cataract inflammation.

Authors:  Srinivas Rao Chennamaneni; Christina Mamalis; Bonnie Archer; Zack Oakey; Balamurali K Ambati
Journal:  J Control Release       Date:  2013-01-13       Impact factor: 9.776

Review 2.  Expression profiles and prognostic value of miRNAs in retinoblastoma.

Authors:  Lara Elis Alberici Delsin; Karina Bezerra Salomao; Julia Alejandra Pezuk; Maria Sol Brassesco
Journal:  J Cancer Res Clin Oncol       Date:  2018-10-22       Impact factor: 4.553

3.  Intraocular pressure changes: an important determinant of the biocompatibility of intravitreous implants.

Authors:  Ling Zou; Ashwin Nair; Hong Weng; Yi-Ting Tsai; Zhibing Hu; Liping Tang
Journal:  PLoS One       Date:  2011-12-14       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.